Abstract
The natural course of MDS varies considerably depending upon patient age and findings at the time of diagnosis. Life expectancy ranges from years in early stages to only a few months in advanced stages. The disease can rapidly progress to acute leukemia, and the prognosis for patients with advanced MDS (RAEB, RAEBT) and therapy-related (secondary) MDS is generally less than 12 months. CMML generally referred to as MDS has recently been reclassified as a myeloproliferative disorder (MPD), although myelodysplastic features are usually present. The median survival is 8–30 months. Since most transplant studies for MDS include CMML, this review will consider CMML as well. While patients with RA or RARS may fair well with conventional treatment, they frequently require transfusion support with red blood cells and platelets which results in iron overload and allosensitization. Prolonged neutropenia may facilitate infections which can significantly increase the risk of post-transplant complications.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anderson, J.E., Appelbaum, F.R., Schoch, G., Gooley, T., Anasetti, C., Bensinger, W.I., Bryant, E., Dean Buckner, C, Chauncey, T, Clift, R.A., Doney, K., Flowers, M., Hansen, J.A., Martin, P.J., Matthews, D.C., Sanders, J.E., Shulman, H., Sullivan, K.M., Witherspoon, R.P., & Storb, R. (1996a) Allogeneic Marrow Transplant for Refractory Anemia: A comparison of two preparative regimens and analysis of prognostic factors.Blood87, 51–58.
Anderson, J.E., Appelbaum, F.R., Schoch, G., Gooley, T., Anasetti, C., Bensinger, W.I., Bryant, E., Dean Buckner, C, Chauncey, T, Clift, R.A., Joachim Deeg, H., Doney, K., Flowers, M., Hansen, J.A., Martin, P.J., Matthews, D.C., Nash, R.A., Sanders, J.E., Shulman, H., Sullivan, K.M., Witherspoon, R.P., & Storb, R. (1996b) Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: A phase 11 study of Busulfan, Cyclophosphamide, and total-body irradiation and analysis of prognostic factors.Journal of Clinical Oncology14, 220–226.
AppeLbaum, F., & Anderson, J. (1998) Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score.Leukemia12, Supplement 1, S25–S29.
Ballen, K.K., Gilliland, D.G., Guinan, E.C., Hsieh, C-C., Parsons, S.K., Rimm, I.J., Ferrara, J.L.M., Bierer, B.E., Weinstein, H.J., & Antin, J.H. (1997) Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia.Bone Marrow Transplantation20, 737–743.
Deeg, H.J., Shulman, H.M., Anderson, J.E., Bryant, E.M., Gooley, T.A., Slattery, J.T., Anasetti, C., Fefer, A., Storb, R., & Appelbaum, F.R. (2000) Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age.Blood95, 1188–1194
Friedberg, J.W., Neuberg, D., Stone, R.M., Alyea, E., Jallow, H., LaCasce, A., Mauch, P.M., Gribben, J.G., Ritz, J., Nadler, L.M., Soiffer, R.J., & Freedman, A.S. (1999) Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin’s lymphoma.Journal of Clinical Oncology17, 3128–3135.
Gassmann, W., Schmitz, N., Loftier, H., & DeWitte, T. (1996) Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes.Seminars in Hematology33, 196–205.
Okamoto, S., Takahashi, S., Wakui, M., Ishida, A., Tanosaki, R., Ikeda, Y., & Asano, S. (1999) Treatment of advanced myelodysplastic syndromes with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation.British Journal of Haematology 104:569–573.
Porter, D.L., Roth, M.S., Lee, S.J., McGarigle, C., Ferrara, J.L.M., & Antin, J.H. (1996) Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation.Bone Marrow Transplantation 18975–980
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Klingemann, HG., Deeg, H.J. (2001). Stem Cell Transplantation for Myelodysplasia. In: Raza, A., Mundle, S.D. (eds) Myelodysplastic Syndromes & Secondary Acute Myelogenous Leukemia. Cancer Treatment and Research, vol 108. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1463-3_9
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1463-3_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5566-3
Online ISBN: 978-1-4615-1463-3
eBook Packages: Springer Book Archive